GOSS Gossamer Bio Inc

In a report released today, Paul Choi from Goldman Sachs maintained a Buy rating on Gossamer Bio (GOSS - Research Report), with a price target of $10.00. The company's shares opened today at $1.79.Choi covers the Healthcare sector, focusing on stocks such as Gossamer Bio, Ascendis Pharma, and FibroGen. According to TipRanks, Choi has an average return of 7.1% and a 51.28% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gossamer Bio with a $9.44 average price target, a 427.37% upside from current levels.
https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-buy-rating-for-gossamer-bio-goss?utm_source=advfn.com&utm_medium=referral